You are here

Home » Content

PEDİATRİK ONKOLOJİ. HASTALARDA ORAL KANDİDA FLORASI VE PROFİLAKTİK TEDAVİNİN ETKİNLİĞİ

Oral candidial flora and effectiveness of prophylactic treatment in pediatric oncologic patients

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1999

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Candida species are the most common causes of fungal infections in immunocompromised patients. The purpose of this study was to investigate oral candidial flora and effectiveness of the prophylactic treatment in pediatric oncologic patients. Thirty four patients with haemotologic or solid malignancy enrolled in the study. The samples were taken from patient's oral mucosa and incubated in Sabouraud's agar. Isolated yeast colonies were typed with classical and disc diffusion methods. Fourteen patients had positive culture for candidiasis. The distribution of candidal species with the classical method was 11 (78,6%) C. albicans, two (14,3%) C. kefyr and one (7,1%) C. (Torulopsus) glabrata. The disc diffusion method identified 12 (85,7%) C. albicans and two (14,3%) C. glabrata from the specimens. The ratio of yeast colony production were 33,3% in patients with prophylactic treatment and 44% in patients without prophylaxis. As a result, the follow-up of oncologic patients both with mucosal candidal culture and systemic fluconasole administration as a prophylaxis would be suitable.
Bookmark/Search this post with
Abstract (Original Language): 
İmmün sistemi baskılanmış kişilerde fırsatçı mantar enfeksiyonlarının en sık nedeni kandidalardır. Bu çalışmada, pediatrik onkolojik hastalarda oral kandida florası ve profilaktik tedavinin etkinliğinin incelenmesi amaçlanmıştır. Bu amaçla çalışmaya hematolojik veya solid tümörü bulunan 34 hasta alındı. Olguların oral mukozasından alınan sürüntüler kloramfenikollü Sabouraud besiyerine ekildi. Kandida tiplendirilmesi klasik ve disk diffüzyon yöntemi ile yapıldı. Olguların 14'ünde maya üremesi görüldü. Klasik yöntemle yapılan tiplendirme sonununda bunların 11 (%78.6)'inin Candida albicans, ikisinin (%14.3) C. kefyr, birinin (%7.1) C. (Torulopsus) glabrata olduğu, disk diffüzyon yöntemi ile ise, 12 (85.7)'sinin C. albicans ve ikisinin (%14.3) C. glabrata olduğu görüldü. Profilaktik tedavi alanların %33.3'ünde maya hücresi ürerken profilaktik tedavi almayanlarda bu oran % 44 idi. SSonuç olarak, onkolojik olguların oral mukozasından kandida için kültür alınarak tak p ed lmes n n ve prof lakt k olarak s stem k flukonazol verilmesin in uygun olacağını düşünmekteyiz.
FULL TEXT (PDF): 
PDF icon arastirmax-pediatrik-onkoloji.hastalarda-oral-kandida-florasi-profilaktik-tedavinin-etkinligi.pdf
  • 1
42-45
  • Turkish

REFERENCES

References: 

1.
Hopp
e JE, Friess D, Niethammer D. Oro i ntesti nal yeast coloni zati on of paed iatric oncolog ic patients duri ng antifungal prophylaxis: result of quant i tat i ve culture and cand i da serology and compar i son of three polyenes. Mycoses 1995; 38: 41-9.
44
Turgu
t Özal Tıp Merkezi Dergisi 6(1):1999
Ukşal ve ark
2. Warren NG, Shadomy HJ. Yeasts of medical i mportance. In: Balows A, Hausler WJ, Herrmann KL, Herrmann KL, Isenberg HD, Shadomy HJ, eds. Manual of Cl ini cal M i crob iology. 5th Ed. Washington: American Soc iety for M icrob i ology 1991: 617-29.
3. Sobczac H. A si mple d i sk-d i ffusion test for d i fferant iati on of yeast spec ies. J Med M i crob iol 1985; 20: 307-16.
4. Hoppe JE, Kl ingeb i el T, Ne ithammer D. Oro i ntest inal yeast colonizati on of paediatri c bone marrow transplant rec ip ients: surve i llance by quanti tative culture and serology. Mycoses 1995; 38: 51-7.
5. Hoegl L, Thoma-Greber E, Rocken M, Kort ing HC. Pers i stent oral cand i dosi s by non-alb i cans cand i da stra i ns i nclud i ng candida glabrata in a human immunodefi c i ency vi rus- i nfected pat ient observed over a peri od of 6 years. Mycoses 1998; 41: 335-8.
6. R i dgden O, Tollemar J. L i posomal amphoteri c i n B (AmB i some®) treatment of invasive fungal i nfections i n i mmuncomprom i sed chi ldren.
Mycoses 1993; 36: 187-92.
7. Schuler U, Mölle M, Ehninger G. Prophylaxe und therap i e von p ilz infektionen i n der onkologie. Mycoses 1995; 38 (Suppl. 1): 45-50.
8. Mucke R, Kaben U, Li bera T, Knauerhase H, Z iegler PG, Hamann D, Stri etzel M. Fluconazole prophylaxi s i n pati ents wi th head and neck tumours undergo ing radiati on and radiochemotherapy. Mycoses 1998; 41:
421-3.
9. De Laurenz i A, Matteocc i A, Lanti A, Pescador L, Bland i lo F, Papetti C. Amphoter i c i n B prophylax i s aga inst fungal i nfect i ons i n neutropen i c pati ents: a single center experi ence from 1980 to 1995. Infecti on 1996;
24: 361-6.
10. Arn ng M, Aul C. Mykose-prophylaxe be neutrozytopen schen pat enten.
Mycoses 1995; 37 (Suppl. 2): 70-6.
11. Bergmann OJ. The demonstrat on of cand dal pseudohyphae n sal vary smears as a method of early d agnos s of oral cand d as s n pat ents w th acute myelo d leukem a. Oral M crob ol Immunol 1996; 11: 362-4.
12. N colatou O, Theodor dou M, Mostrou G, Velegrak A, Legak s NJ. Oral les ons n ch ldren w th per natally acqu red human mmunodef c ency v rus infecti on. J Oral Pathol Med 1999; 28: 49-53.
13. Taylor TL. Nystat n prophylax s n mmunocomprom sed ch ldren. Ann Pharmacother 1996; 30: 534-5.

Thank you for copying data from http://www.arastirmax.com